Compare Stocks: SVRA, ACAD, CELC, and TNGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.40 +0.6%	$24.39	$19.69 ▼ $29.65	$5.06B	0.81	1.68 million shs	1.56 million shs
CELC Celcuity	$91.35 -1.5%	$94.57	$44.42 ▼ $151.02	$4.46B	0.21	1.11 million shs	161,309 shs
SVRA Savara	$5.70 -2.3%	$5.62	$2.43 ▼ $7.01	$1.17B	0.29	1.62 million shs	481,436 shs
TNGX Tango Therapeutics	$27.05 -0.1%	$28.47	$6.25 ▼ $34.39	$3.91B	1.16	3.55 million shs	1.02 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+12.91%	+11.40%	+33.99%	+18.74%
CELC Celcuity	0.00%	+7.42%	-13.75%	-26.15%	+102.24%
SVRA Savara	0.00%	+6.78%	-3.32%	+13.87%	+120.83%
TNGX Tango Therapeutics	0.00%	-0.40%	-12.85%	+15.29%	+309.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.40 +0.6%	$24.39	$19.69 ▼ $29.65	$5.06B	0.81	1.68 million shs	1.56 million shs
CELC Celcuity	$91.35 -1.5%	$94.57	$44.42 ▼ $151.02	$4.46B	0.21	1.11 million shs	161,309 shs
SVRA Savara	$5.70 -2.3%	$5.62	$2.43 ▼ $7.01	$1.17B	0.29	1.62 million shs	481,436 shs
TNGX Tango Therapeutics	$27.05 -0.1%	$28.47	$6.25 ▼ $34.39	$3.91B	1.16	3.55 million shs	1.02 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+12.91%	+11.40%	+33.99%	+18.74%
CELC Celcuity	0.00%	+7.42%	-13.75%	-26.15%	+102.24%
SVRA Savara	0.00%	+6.78%	-3.32%	+13.87%	+120.83%
TNGX Tango Therapeutics	0.00%	-0.40%	-12.85%	+15.29%	+309.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.82	Moderate Buy	$33.31	13.30% Upside
CELC Celcuity	2.82	Moderate Buy	$155.18	69.87% Upside
SVRA Savara	2.88	Moderate Buy	$10.14	78.10% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$42.15	55.83% Upside

Current Analyst Ratings Breakdown

Latest SVRA, ACAD, CELC, and TNGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $39.00
8/6/2026	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $37.00
8/5/2026	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$23.00 ➝ $25.00
8/5/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/5/2026	ACAD ACADIA Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$35.00 ➝ $36.00
7/29/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/29/2026	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.50
7/21/2026	ACAD ACADIA Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$34.00 ➝ $36.00
7/17/2026	SVRA Savara	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.73	$0.89 per share	32.93	$7.25 per share	4.05
CELC Celcuity	N/A	N/A	N/A	N/A	$2.17 per share	N/A
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A
TNGX Tango Therapeutics	$62.38M	62.73	N/A	N/A	$2.57 per share	10.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	13.24	29.69	23.76	33.42%	9.03%	6.79%	N/A
CELC Celcuity	-$177.04M	-$3.90	N/A	4,567.60	N/A	N/A	-244.61%	-50.22%	8/13/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.56	N/A	N/A	N/A	N/A	-87.19%	-66.42%	8/12/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.83	N/A	N/A	N/A	N/A	-41.54%	-33.44%	8/11/2026 (Estimated)

Latest SVRA, ACAD, CELC, and TNGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	N/A	N/A	N/A	$4.42 million	N/A
8/12/2026	Q2 2026	SVRA Savara	-$0.1425	N/A	N/A	N/A	$2.00 million	N/A
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	N/A	N/A	N/A	$1.56 million	N/A
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
5/14/2026	Q1 2026	CELC Celcuity	-$1.07	-$0.97	+$0.10	-$0.97	$2.94 million	N/A
5/13/2026	Q1 2026	TNGX Tango Therapeutics	-$0.32	-$0.32	N/A	-$0.32	$0.58 million	N/A
5/12/2026	Q1 2026	SVRA Savara	-$0.14	-$0.15	-$0.01	-$0.15	$0.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
CELC Celcuity	6.04	12.31	12.31
SVRA Savara	0.17	13.47	13.47
TNGX Tango Therapeutics	N/A	27.38	27.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
CELC Celcuity	63.33%
SVRA Savara	87.93%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
CELC Celcuity	13.33%
SVRA Savara	5.30%
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
CELC Celcuity	40	48.77 million	42.27 million	Optionable
SVRA Savara	20	204.93 million	194.07 million	Optionable
TNGX Tango Therapeutics	90	144.65 million	135.25 million	Optionable

SVRA, ACAD, CELC, and TNGX Headlines

Recent News About These Companies

Tango Therapeutics Announces Executive Chair Barbara Weber’s Departure

August 9 at 8:47 AM | theglobeandmail.com

The Manufacturers Life Insurance Company Boosts Holdings in Tango Therapeutics, Inc. $TNGX

August 9 at 4:48 AM | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading Down 6.1% - What's Next?

August 7 at 12:39 PM | marketbeat.com

Tango Therapeutics Announces Executive Chair Transition

August 6, 2026 | globenewswire.com

Most and least shorted mid- to mega-cap healthcare stocks at the end of July

August 3, 2026 | seekingalpha.com

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

August 3, 2026 | zacks.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Moderate Buy" from Analysts

August 3, 2026 | americanbankingnews.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Moderate Buy" by Analysts

August 3, 2026 | marketbeat.com

Perceptive Advisors LLC Has $16.91 Million Stock Holdings in Tango Therapeutics, Inc. $TNGX

August 2, 2026 | marketbeat.com

Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by Janus Henderson Group PLC

August 2, 2026 | marketbeat.com

DV Trading LLC Takes $6.29 Million Position in Tango Therapeutics, Inc. $TNGX

August 2, 2026 | marketbeat.com

Stempoint Capital LP Acquires Shares of 200,919 Tango Therapeutics, Inc. $TNGX

July 30, 2026 | marketbeat.com

ADAR1 Capital Management LLC Sells 90,021 Shares of Tango Therapeutics, Inc. $TNGX

July 30, 2026 | marketbeat.com

Tango Therapeutics (TNGX) to Release Quarterly Earnings on Tuesday

July 28, 2026 | marketbeat.com

Tango Therapeutics, Inc. $TNGX Shares Sold by Siren L.L.C.

July 24, 2026 | marketbeat.com

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%

July 22, 2026 | zacks.com

Tango Therapeutics, Inc. $TNGX is Trv Gp Iv LLC's 2nd Largest Position

July 21, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 6.1% - Time to Buy?

July 17, 2026 | marketbeat.com

Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues

July 15, 2026 | finance.yahoo.com

JPMorgan Chase & Co. Initiates Coverage on Tango Therapeutics (NASDAQ:TNGX)

July 15, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 8.7% - Here's What Happened

July 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, ACAD, CELC, and TNGX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$29.40 +0.19 (+0.64%)

As of 01:43 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Celcuity NASDAQ:CELC

$91.35 -1.43 (-1.54%)

As of 01:43 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Savara NASDAQ:SVRA

$5.70 -0.14 (-2.32%)

As of 01:43 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Tango Therapeutics NASDAQ:TNGX

$27.05 -0.02 (-0.07%)

As of 01:43 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVRA, ACAD, CELC, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVRA, ACAD, CELC, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVRA, ACAD, CELC, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, ACAD, CELC, and TNGX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Celcuity NASDAQ:CELC

Savara NASDAQ:SVRA

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVRA, ACAD, CELC, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVRA, ACAD, CELC, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVRA, ACAD, CELC, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, ACAD, CELC, and TNGX Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Celcuity NASDAQ:CELC

Savara NASDAQ:SVRA

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools